.png){kind=icon}
返回
Reference pricing with endogenous generic entry
.png){kind=icon}
OA
AI
DOI：10.1016/j.jhealeco.2016.04.003.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Reference pricing intends to reduce pharmaceutical expenditures by increasing demand elasticity and stimulating generic competition. We develop a novel model where a brand-name producer competes in prices with several generics producers in a market with brand-biased and brand-neutral consumers. Comparing with coinsurance, we show that reference pricing, contrary to policy makers' intentions, discourages generic entry, as it induces the brand-name producer to price more aggressively. Thus, the net effect of reference pricing on drug prices is ambiguous, implying that reference pricing can be counterproductive in reducing expenditures. However, under price regulation, we show that reference pricing may stimulate generic entry, since a binding price cap weakens the aggressive price response by the brand name producer. This may explain mixed empirical results on the competitive effects of reference pricing. Finally, we show that reference pricing may be welfare improving when accounting for brand preferences despite its adverse effects on entry and prices. (C) 2016 Elsevier B.V. All rights reserved.
Keyword:
Pharmaceuticals
Reimbursement schemes
Generic entry
Brand-biased consumers
Drug expenditures
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
3.6
论文数:
3.4K
被引数:
8.6K
机构
引用论文
Occurrence and characterization of peptaibols from Trichoderma citrinoviride, an endophytic fungus of cork oak, using electrospray ionization quadrupole time-of-flight mass spectrometry.png)
Microbiology
OAAI
MicrobiologyIF0
OAAI分享收藏分享收藏City Living and Psychotic Disorders—Implications of Global Heterogeneity for Theory Development
PREAI
分享收藏
查看更多内容